Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 485

1.

Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.

Resino S, Bellón JM, Ramos JT, Navarro ML, Martín-Fontelos P, Cabrero E, Muñoz-Fernández MA.

Pediatr Infect Dis J. 2004 Oct;23(10):923-30.

PMID:
15602192
2.

Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.

Resino S, Bellón JM, Ramos JT, Gonzalez-Rivera M, de José MI, González MI, Gurbindo D, Mellado MJ, Cabrero E, Muñoz-Fernández MA.

J Antimicrob Chemother. 2004 Nov;54(5):921-31. Epub 2004 Oct 7.

PMID:
15472006
3.

Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.

Luis Jiménez J, Resino S, Martinez-Colom A, Bellón JM, Angeles Muñoz-Fernández M; Spanish Group of Paediatric HIV Infection..

J Antimicrob Chemother. 2005 Dec;56(6):1081-6. Epub 2005 Sep 29.

PMID:
16195257
4.

Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

Frange P, Briand N, Avettand-fenoel V, Veber F, Moshous D, Mahlaoui N, Rouzioux C, Blanche S, Chaix ML.

Pediatr Infect Dis J. 2011 Aug;30(8):684-8. doi: 10.1097/INF.0b013e31821752d6.

PMID:
21427626
5.

Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler Palacín P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA.

J Antimicrob Chemother. 2008 Jan;61(1):183-90. Epub 2007 Nov 19.

PMID:
18025025
6.

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.

J Clin Virol. 2007 Feb;38(2):131-8. Epub 2007 Jan 4.

PMID:
17208042
7.

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine..

Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32.

8.
9.

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.

Antivir Ther. 2008;13(7):927-36.

PMID:
19043927
10.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children..

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
11.

Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, Benson C, King KR, Murphy RL, Brun SC.

AIDS. 2004 Mar 26;18(5):775-9.

PMID:
15075512
12.

Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.

Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, Gladysz A, Cohen-Codar I, Van PN, Taburet AM, Rouzioux C, Delfraissy JF; MONARK Study Group..

Antivir Ther. 2009;14(1):93-7.

PMID:
19320241
13.

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

Bongiovanni M, Bini T, Adorni F, Meraviglia P, Capetti A, Tordato F, Cicconi P, Chiesa E, Cordier L, Cargnel A, Landonio S, Rusconi S, d'Arminio Monforte A.

Antivir Ther. 2003 Jun;8(3):209-14.

PMID:
12924537
14.

Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad.

Int J Antimicrob Agents. 2005 Jul;26(1):88-91.

PMID:
15878262
15.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15821394
16.

Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy.

Nachman SA, Lindsey JC, Pelton S, Mofenson L, McIntosh K, Wiznia A, Stanley K, Yogev R.

Arch Pediatr Adolesc Med. 2002 May;156(5):497-503.

PMID:
11980557
18.

High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.

Paredes R, Puig T, Arnó A, Negredo E, Balagué M, Bonjoch A, Jou A, Tuldrà A, Tural C, Sirera G, Veny A, Romeu J, Ruiz L, Clotet B.

J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):132-8.

PMID:
10843526
19.

Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.

Bongiovanni M, Bini T, Chiesa E, Cicconi P, Adorni F, Monforte d'Arminio A.

Antiviral Res. 2004 Apr;62(1):53-6.

PMID:
15026202
20.

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, Lazzari Ed, Gatell JM; ATAZIP Study Group..

J Acquir Immune Defic Syndr. 2009 May 1;51(1):29-36. doi: 10.1097/QAI.0b013e31819a226f.

PMID:
19390327

Supplemental Content

Support Center